Loading
Latest filing published 30 Dec 2021 for Pardes Biosciences, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
All filings by Daniel Dubin on record concern Pardes Biosciences, Inc., in the capacity of board member. Altogether 2 filings, all relating to 23 December 2021.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 30 December 2021: a transaction, in Pardes Biosciences, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations